LAB
STANDARD BIOTOOLS INC.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NegativeStandard BioTools is undergoing a transformational all-stock merger with Treeline Biosciences (closing expected by end-2026) that will effectively convert the company into a biotech pipeline player with ~$450M in net cash. However, Q2 2026 results missed both earnings (-$0.04 vs. -$0.01 est.) and revenue ($20.1M vs. $21.0M est.), with the company withdrawing full-year guidance amid strategic repositioning and divestiture of its Mass Cytometry business.
Red flags
- •Q2 2026 earnings miss of $0.03/share and revenue miss of ~4.4% vs. consensus
- •Revenue declined 7.6% year-over-year to $20.1M; net loss from continuing operations of $21.5M
- •Full-year 2026 guidance withdrawn due to strategic shifts and pending merger uncertainty
- •Company divesting core legacy business (Mass Cytometry) to advance merger, signaling operational contraction
- •Analyst consensus neutral to bearish: $1.35 price target with 'Hold' rating; TipRanks rates LAB as 'Neutral' citing weak operating performance and ongoing cash burn despite strong balance sheet
- •Merger consummation contingent on regulatory approval and shareholder vote; financing and integration risks remain
Fund 13D/13G Filings (2)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).
| Fund | Form | ∆ Shares | % of Class | Since Filing | Filed | Src |
|---|---|---|---|---|---|---|
| Viking Global | SC 13D | +0 | 15.0% | -30.5% vs SPY -27.4% abs | 2026-06-12 | ↗ |
| Viking Global | SC 13G/A | — | 15.0% | -29.0% vs SPY -23.5% abs | 2026-05-15 | ↗ |